A Phase 2 trial of sevasemten in children and adolescents with Duchenne previously treated with gene therapy

Edgewise Therapeutics

A Movement in Muscle

Search for:
Clinical Trials
Careers
Investors & News
Menu
Disease Areas

Muscular Dystrophy

Hypertrophic Cardiomyopathy

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.
Explore Muscle

Science & Pipeline

Pipeline

Sevasemten

EDG-7500

Clinical Trials

Posters & Presentations

All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.
Explore our Science

Patients & Families

Support for Becker

Support for Duchenne

Support for HCM

Patient Stories

We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.
Read their Stories

Company

Leadership Team

Careers

Contact Us

Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.
Learn More

Corporate Profile

News

Events & Presentations

Analyst Coverage

Stock Info

Stock Quote

Stock Chart

Historical Stock Quote

Investment Calculator

Financials

Quarterly Results

SEC Filings

Governance

Governance Documents

Committee Composition

Resources

Investor FAQs

Investor Email Alerts

Investor Contacts

August 7, 2024 by

Phase 2 Study of EDG-5506 in Children and Adolescents with Duchenne Muscular Dystrophy Previously Treated with Gene Therapy